

Xin-Ting Sang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8115612/publications.pdf>

Version: 2024-02-01

114
papers

2,516
citations

236925

25
h-index

265206

42
g-index

125
all docs

125
docs citations

125
times ranked

3616
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. <i>Journal of Hepatology</i> , 2014, 61, 840-849.	3.7	131
2	Intraductal papillary neoplasm of the bile duct. <i>World Journal of Gastroenterology</i> , 2013, 19, 8595.	3.3	126
3	Comprehensive analysis of a ceRNA network reveals potential prognostic cytoplasmic lncRNAs involved in HCC progression. <i>Journal of Cellular Physiology</i> , 2019, 234, 18837-18848.	4.1	103
4	Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. , 2021, 9, e003334.		101
5	DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. <i>Theranostics</i> , 2019, 9, 7251-7267.	10.0	99
6	Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 414-424.	1.5	93
7	Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: A review. <i>Cell Proliferation</i> , 2020, 53, e12772.	5.3	80
8	Long non-coding RNA expression profiles of hepatitis C virus-related dysplasia and hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 43770-43778.	1.8	79
9	Alterations in DNA Damage Repair Genes in Primary Liver Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4701-4711.	7.0	74
10	Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma. <i>Nature Communications</i> , 2018, 9, 894.	12.8	67
11	Coffee and cancer risk: A meta-analysis of prospective observational studies. <i>Scientific Reports</i> , 2016, 6, 33711.	3.3	66
12	Mps1/TTK: a novel target and biomarker for cancer. <i>Journal of Drug Targeting</i> , 2017, 25, 112-118.	4.4	59
13	Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. <i>Journal of Hematology and Oncology</i> , 2019, 12, 42.	17.0	58
14	Prognostic significance of the fibrinogen-to-albumin ratio in gallbladder cancer patients. <i>World Journal of Gastroenterology</i> , 2018, 24, 3281-3292.	3.3	56
15	Hepatobiliary cystadenomas and cystadenocarcinomas: a report of 33 cases. <i>Liver International</i> , 2011, 31, 1337-1344.	3.9	53
16	Transcriptional landscape of cholangiocarcinoma revealed by weighted gene coexpression network analysis. <i>Briefings in Bioinformatics</i> , 2021, 22, .	6.5	46
17	Combination treatment including targeted therapy for advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 71036-71051.	1.8	44
18	Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression. <i>BMC Cancer</i> , 2018, 18, 766.	2.6	42

#	ARTICLE	IF	CITATIONS
19	Construction of a lipid metabolism-related and immune-associated prognostic signature for hepatocellular carcinoma. <i>Cancer Medicine</i> , 2020, 9, 7646-7662.	2.8	42
20	Combined hepatocellular cholangiocarcinoma: Controversies to be addressed. <i>World Journal of Gastroenterology</i> , 2016, 22, 4459.	3.3	42
21	Mutational spectrum and precision oncology for biliary tract carcinoma. <i>Theranostics</i> , 2021, 11, 4585-4598.	10.0	39
22	Prognostic significance of combined preoperative fibrinogen and CA199 in gallbladder cancer patients. <i>World Journal of Gastroenterology</i> , 2018, 24, 1451-1463.	3.3	35
23	Time-restricted feeding causes irreversible metabolic disorders and gut microbiota shift in pediatric mice. <i>Pediatric Research</i> , 2019, 85, 518-526.	2.3	32
24	Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy. <i>BMC Medicine</i> , 2021, 19, 154.	5.5	32
25	<p>Development and Verification of the Hypoxia-Related and Immune-Associated Prognosis Signature for Hepatocellular Carcinoma</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 315-330.	3.7	31
26	Magnesium isoglycyrrhizinate inhibits inflammatory response through STAT3 pathway to protect remnant liver function. <i>World Journal of Gastroenterology</i> , 2015, 21, 12370.	3.3	31
27	Alteration in gut microbiota caused by time-restricted feeding alleviate hepatic ischaemia reperfusion injury in mice. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 1714-1722.	3.6	30
28	Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 434-442.	1.5	28
29	Liver graft rejection following immune checkpoint inhibitors treatment: a review. <i>Medical Oncology</i> , 2019, 36, 94.	2.5	27
30	N6-methyladenosine associated prognostic model in hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 633-633.	1.7	27
31	CeRNA regulatory network-based analysis to study the roles of noncoding RNAs in the pathogenesis of intrahepatic cholangiocellular carcinoma. <i>Aging</i> , 2020, 12, 1047-1086.	3.1	27
32	Development of an immune-related prognostic index associated with hepatocellular carcinoma. <i>Aging</i> , 2020, 12, 5010-5030.	3.1	26
33	A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape. <i>Genome Medicine</i> , 2022, 14, 20.	8.2	26
34	Hepatitis B virus infection and the risk of nonalcoholic fatty liver disease: a meta-analysis. <i>Oncotarget</i> , 2017, 8, 107295-107302.	1.8	25
35	Response of <i>BRCA1</i>-mutated gallbladder cancer to olaparib: A case report. <i>World Journal of Gastroenterology</i> , 2016, 22, 10254.	3.3	24
36	Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice. <i>Annals of Translational Medicine</i> , 2019, 7, 467-467.	1.7	24

#	ARTICLE	IF	CITATIONS
37	The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A review. <i>Cell Proliferation</i> , 2020, 53, e12791.	5.3	23
38	The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study. <i>Frontiers in Oncology</i> , 2021, 11, 646979.	2.8	23
39	Prognostic impact of the red cell distribution width in esophageal cancer patients: A systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2018, 24, 2120-2129.	3.3	23
40	Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers. , 2021, 9, e001942.		22
41	LncRNA CYTOR affects the proliferation, cell cycle and apoptosis of hepatocellular carcinoma cells by regulating the miR-125b-5p/KIAA1522 axis. <i>Aging</i> , 2021, 13, 2626-2639.	3.1	22
42	Distinct hepatitis B virus integration patterns in hepatocellular carcinoma and adjacent normal liver tissue. <i>International Journal of Cancer</i> , 2017, 140, 1324-1330.	5.1	19
43	GTSE1, CDC20, PCNA, and MCM6 Synergistically Affect Regulations in Cell Cycle and Indicate Poor Prognosis in Liver Cancer. <i>Analytical Cellular Pathology</i> , 2019, 2019, 1-13.	1.4	19
44	Tea consumption and the risk of biliary tract cancer: a systematic review and dose-response meta-analysis of observational studies. <i>Oncotarget</i> , 2017, 8, 39649-39657.	1.8	17
45	Safety, feasibility, and efficacy of associating liver partition and portal vein ligation for staged hepatectomy in treating hepatocellular carcinoma: a systematic review. <i>Annals of Translational Medicine</i> , 2020, 8, 1246-1246.	1.7	17
46	Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2020, 89, 107135.	3.8	17
47	Feature Learning Based Random Walk for Liver Segmentation. <i>PLoS ONE</i> , 2016, 11, e0164098.	2.5	16
48	The diagnostic and prognostic role of RhoA in hepatocellular carcinoma. <i>Aging</i> , 2019, 11, 5158-5172.	3.1	16
49	Dr.VIS v2.0: an updated database of human disease-related viral integration sites in the era of high-throughput deep sequencing. <i>Nucleic Acids Research</i> , 2015, 43, D887-D892.	14.5	15
50	Continuous Pringle maneuver does not affect outcomes of patients with hepatocellular carcinoma after curative resection. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e321-e330.	1.1	15
51	Liver segmentation from CT images using a sparse priori statistical shape model (SP-SSM). <i>PLoS ONE</i> , 2017, 12, e0185249.	2.5	15
52	Molecular subtypes based on immune-related genes predict the prognosis for hepatocellular carcinoma patients. <i>International Immunopharmacology</i> , 2021, 90, 107164.	3.8	15
53	Edmondson grade predicts survival of patients with primary clear cell carcinoma of liver after curative resection: A retrospective study with long-term follow-up. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e312-e320.	1.1	14
54	Reassessment of different criteria for diagnosing post-hepatectomy liver failure: a single-center study of 1683 hepatectomy. <i>Oncotarget</i> , 2017, 8, 89269-89277.	1.8	14

#	ARTICLE	IF	CITATIONS
55	<p>Preoperative neutrophil"lymphocyte and platelet"lymphocyte ratios as independent predictors of T stages in hilar cholangiocarcinoma</p>. Cancer Management and Research, 2019, Volume 11, 5157-5162.	1.9	14
56	Systematic review and meta-analysis: cholecystectomy and the risk of cholangiocarcinoma. Oncotarget, 2017, 8, 59648-59657.	1.8	13
57	Severe adult ileosigmoid intussusception prolapsing from the rectum: A case report. Cases Journal, 2008, 1, 198.	0.4	12
58	Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer. Nature Communications, 2021, 12, 4753.	12.8	12
59	Gallbladder papillary neoplasms share pathological features with intraductal papillary neoplasm of the bile duct. Oncotarget, 2017, 8, 31532-31539.	1.8	12
60	The fusion landscape of hepatocellular carcinoma. Molecular Oncology, 2019, 13, 1214-1225.	4.6	11
61	The application of single-cell sequencing technology in the diagnosis and treatment of hepatocellular carcinoma. Annals of Translational Medicine, 2019, 7, 790-790.	1.7	11
62	Peripheral primitive neuroectodermal tumors arising in the pancreas: the first case report in Asia and a review of the 14 total reported cases in the world. Hepatobiliary Surgery and Nutrition, 2013, 2, 51-60.	1.5	11
63	Diagnosis and treatment of hepatic angiomyolipoma. Hepatobiliary Surgery and Nutrition, 2012, 1, 19-24.	1.5	10
64	Complete or partial split in associating liver partition and portal vein ligation for staged hepatectomy: A systematic review and meta-analysis. World Journal of Gastroenterology, 2019, 25, 6016-6024.	3.3	9
65	A new avenue for obtaining insight into the functional characteristics of long noncoding RNAs associated with estrogen receptor signaling. Scientific Reports, 2016, 6, 31716.	3.3	8
66	The Prognostic Value of Systemic Inflammation Response Index in Cholangiocarcinoma Patients. Cancer Management and Research, 2021, Volume 13, 6263-6277.	1.9	8
67	Identification of hub genes involved in the development of hepatocellular carcinoma by transcriptome sequencing. Oncotarget, 2017, 8, 60358-60367.	1.8	8
68	T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy. American Journal of Cancer Research, 2020, 10, 4585-4606.	1.4	8
69	A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer. Cancer Immunology, Immunotherapy, 2022, , 1.	4.2	8
70	Prediction and identification of tumor-specific noncoding RNAs from human UniGene. Medical Oncology, 2010, 27, 894-898.	2.5	7
71	<p>Prognostic Nomogram That Predicts Overall Survival of Patients with Distal Cholangiocarcinoma After Pancreatoduodenectomy</p>. Cancer Management and Research, 2020, Volume 12, 10303-10310.	1.9	7
72	Association of a novel PKHD1 mutation in a family with autosomal dominant polycystic liver disease. Annals of Translational Medicine, 2021, 9, 120-120.	1.7	7

#	ARTICLE	IF	CITATIONS
73	Comparative microbial antibiotic resistome between urban and deep forest environments. <i>Environmental Microbiology Reports</i> , 2021, 13, 503-508.	2.4	7
74	Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma. <i>Journal of Cancer</i> , 2021, 12, 1555-1562.	2.5	7
75	Management of intrahepatic recurrence after resection for hepatocellular carcinoma exceeding the barcelona clinic liver cancer criteria. <i>Oncotarget</i> , 2017, 8, 110406-110414.	1.8	7
76	Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 785535.	2.8	6
77	Acute kidney injury after associating liver partition and portal vein ligation for staged hepatectomy for hepatocellular carcinoma: two case reports and a literature review. <i>Annals of Translational Medicine</i> , 2019, 7, 795-795.	1.7	5
78	<p>Prognostic Significance of the Preoperative Lymphocyte to Monocyte Ratio in Patients with Gallbladder Carcinoma</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 3271-3283.	1.9	5
79	Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 673248.	4.8	4
80	CMTTdb: the cancer molecular targeted therapy database. <i>Annals of Translational Medicine</i> , 2019, 7, 667-667.	1.7	4
81	Prognostic value and underlying mechanism of KIAA0101 in hepatocellular carcinoma: database mining and co-expression analysis. <i>Aging</i> , 2020, 12, 16420-16436.	3.1	4
82	Î³-glutamyl transferase-to-platelet ratio based nomogram predicting overall survival of gallbladder carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 1014-1030.	2.0	4
83	MetastamiRs: A promising choice for antihepatocellular carcinoma nucleic acid drug development. <i>Hepatology Research</i> , 2017, 47, 80-94.	3.4	3
84	<p>Preoperative Bilirubin-Adjusted Carbohydrate Antigen 19-9 as a Prognostic Factor for Extrahepatic Cholangiocarcinoma Patients at a Single Center</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 411-417.	1.9	3
85	A Nomogram to Predict Individual Survival of Patients with Liver-Limited Metastases from Gastroenteropancreatic Neuroendocrine Neoplasms: A US Population-Based Cohort Analysis and Chinese Multicenter Cohort Validation Study. <i>Neuroendocrinology</i> , 2022, 112, 263-275.	2.5	3
86	Construction and validation of a prognostic signature using CNV-driven genes for hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 765-765.	1.7	3
87	Genomics and translational precision oncology for 803 patients with biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4589-4589.	1.6	3
88	Signature based on molecular subtypes of deoxyribonucleic acid methylation predicts overall survival in gastric cancer. <i>World Journal of Gastroenterology</i> , 2020, 26, 6414-6430.	3.3	3
89	<p>Preoperative Immune Prognostic Index</p> Can Predict the Clinical Outcomes of Patients with Gallbladder Cancer: Single-Center Experience</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 12137-12150.	1.9	2
90	Novel nomograms based on immune and stromal scores for predicting the disease-free and overall survival of patients with hepatocellular carcinoma undergoing radical surgery. <i>Journal of Surgical Oncology</i> , 2020, 122, 1569-1579.	1.7	2

#	ARTICLE	IF	CITATIONS
91	Hepatobiliary case report and literature review of hepatic reactive lymphoid hyperplasia with positive anti-smooth muscle antibody and anti-nuclear antibody tests. <i>Translational Cancer Research</i> , 2019, 8, 1001-1005.	1.0	2
92	Identification of WDFY3 Neoantigens as Prognostic Markers in Longterm Survivors of Extrahepatic Cholangiocarcinoma. <i>Current Cancer Drug Targets</i> , 2020, 20, 875-886.	1.6	2
93	Conversion therapy of stage IVb unresectable gallbladder carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 335-337.	1.5	2
94	CK20 and lymph node involvement predict adverse outcome of malignant intraductal papillary neoplasm of the bile duct. <i>Histology and Histopathology</i> , 2020, 35, 449-456.	0.7	2
95	Lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma: A large real-world study from two centers.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16155-e16155.	1.6	2
96	Multidisciplinary management of hepatobiliary tumors in the era of precision medicine. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 381-382.	1.3	1
97	Paraneoplastic leukemoid reaction in a patient with sarcomatoid hepatocellular carcinoma: A case report. <i>World Journal of Clinical Cases</i> , 2019, 7, 1330-1336.	0.8	1
98	Association of chronic liver disease with the prognosis of COVID-19 patients. <i>Journal of Hepatology</i> , 2021, , .	3.7	1
99	Diagnosis and treatment of a diaphragmatic pheochromocytoma: A case report. <i>International Journal of Surgery Case Reports</i> , 2020, 71, 78-81.	0.6	1
100	Threonine and tyrosine kinase may serve as a prognostic biomarker for gallbladder cancer. <i>World Journal of Gastroenterology</i> , 2017, 23, 5787.	3.3	1
101	Laparoscopic hepatectomy for patients who received enterostomy. <i>Journal of Minimal Access Surgery</i> , 2019, 15, 325.	0.7	1
102	A call for scientific integrity. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 17, 205-206.	1.5	0
103	Construction of a new immune-related signature based on three lncRNAs as the factor for prognosis prediction of hepatocellular carcinoma. <i>Clinical and Translational Medicine</i> , 2020, 10, e101.	4.0	0
104	Letter to the Editor: Is Aspirin a Drug or Just a Marker for Biliary Cancer?. <i>Hepatology</i> , 2021, 74, 2924-2924.	7.3	0
105	Racial/Ethnic Differences in the 21-Gene Recurrence Score Assay Among Women With Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1248.	7.1	0
106	Potential application of neogalactosylalbumin in positron emission tomography evaluation of liver function. <i>World Journal of Gastroenterology</i> , 2017, 23, 4278.	3.3	0
107	Gallbladder carcinoma post gallbladder-preserving cholecystolithotomy: a case report. <i>Hepatobiliary Surgery and Nutrition</i> , 2012, 1, 61-3.	1.5	0
108	Twenty-eight years of repeated relapse of gastrointestinal stromal tumor. <i>Hepatobiliary Surgery and Nutrition</i> , 2013, 2, 232-3.	1.5	0

#	ARTICLE	IF	CITATIONS
109	Multiple liver lesions with dormant submandibular gland nodule. <i>Hepatobiliary Surgery and Nutrition</i> , 2013, 2, 284-5.	1.5	0
110	Large liver mass in a patient with latent colon cancer. <i>Hepatobiliary Surgery and Nutrition</i> , 2014, 3, 50-1.	1.5	0
111	Identification of TMB, CD8 T cell abundance, and homologous repair pathway mutation frequency as predictors of the benefit-toxicity ratio of anti-PD-1/PD-L1 therapy. <i>Clinical and Translational Medicine</i> , 2021, 11, e598.	4.0	0
112	Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency. <i>Hepatology</i> , 2022, 75, 1058-1059.	7.3	0
113	Ultrasound-Guided Continuous Thoracic Paravertebral Block Improves Patient's Quality of Recovery After Open Hepatectomy: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Chinese Medical Sciences Journal</i> , 2022, 37, 15.	0.4	0
114	Genomic characterization and translational immunotherapy of microsatellite instability-high (MSI-H) in cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 4101-4101.	1.6	0